Background
Angiomyofibroblastoma (AMF) is a rare soft-tissue neoplasm that most frequently affects the lower genital tracts of young to middle-aged women. This tumor belongs to the group of genital mesenchymal tumors [
1]. These tumors commonly involve the vulva, perineum, vagina, uterine cervix [
2‐
4] and the inguinoscrotal regions of men [
5], but only rarely occur in the pelvis or retroperitoneum. Rare recurrences of AMF after excision have been reported in the literature [
6].Here, we report a case of a giant AMF in an uncommon location, namely, the pelvic region. We also emphasize the difficulty in making an accurate preoperative diagnosis. The differential diagnosis for such a tumor includes an aggressive angiomyxoma (AAM), which unlike AMF, does not have well-defined margins.
Discussion
AMF is a rare, benign, soft-tissue tumor that shows myofibroblastic differentiation and represents neoplastic proliferation of stromal cells. AMF was first described by Fletcher et al. in 1992 [
1]. AMF is composed of myofibroblastic cells and prominent thin-walled blood vessels within a fibromxyoid stroma. Its cause and pathogenesis are unknown at present. Since AMF is rare, no statistical data are available about its incidence in the general population. In most reports, AMF has occurred in women aged between 20 and 50 years, i.e., during the reproductive years [
1,
2]. There are very rare reports of AMF occurring in male patients [
5,
7]. Most cases of AMF are benign, and only one case with sarcomatous transformation has ever been reported [
8]. A rare lipomatous variant of AMF with local invasion has also been reported [
9,
10].
In most patients, AMF presents as a painless neoplasm located in the superficial regions of the lower female genital tract, such as the vulva and vagina [
4], and are therefore easily detected. Tumors arising in the cervix, uteri or urethral region sometimes present with obstructive symptoms [
11]. Tumors in the pelvis, iliac fossa or peritoneal cavity are extremely rare, and usually grow insidiously and reach a massive size before they are detected [
12‐
15]. Their greatest dimensions have ranged from 3.8 to 25 cm [
12‐
15]. To our knowledge, only four cases of pelvic AMF have been reported at least so far (Table
1). Table
1 summarizes the major clinical and pathological features of previously reported cases. Similar to AMFs arising in other sites, the pelvic AMFs were well demarcated.
Table 1
Clinical features of female pelvic AMF
| 48 | Posterior perivesical space | 3.8 × 3.5 × 2.8 | Not mentioned |
| 28 | Pelvic retroperitoneum | 12 × 9.6 × 8 | 1 year |
| 28 | Pelvic cavity | 25 × 14 × 4 | 2 years |
| 49 | Ischiorectal fossa | 5.5 × 4.3 × 2 | 2 years |
Several reports have analyzed the imaging features of AMFs. On perineal ultrasonography, AMFs appear as a soft-tissue mass with inhomogeneous mixed echogenicity, which corresponds to the cellular inhomogeneity found on histopathological examination. Therefore, the ultrasonographic characteristics of AMFs may help to differentiate them from other mesenchymal neoplasms [
16]. On CT imaging, AMFs most likely show moderate-to-strong enhancement, which may reflect the prominent vascularity of these tumors [
16]. There have been three cases of AMF which showed well-defined margins and heterogeneous or homogeneous intermediate signal intensity on CT. In the current case, the small, hypoechoic area inside the mass observed on ultrasound examination may be attributable to the flesh-like structures seen on gross examination.
IHC showed that the tumor expressed estrogen and progesterone receptors, which suggests that it might have originated as a neoplastic proliferation of hormonally responsive mesenchymal cells.
As AMF has a benign clinical course, it should be differentiated from other tumor-like lesions of the vulvovaginal region including Bartholin cysts,benign lipoma,fibroepithelial stromal polyps and cellular angiofibromas[
1‐
4,
9,
10].
In the present case, AMF could be readily distinguished from Bartholin cysts and fibroepithelial stromal polyps according to histopathological and immunohistochemical findings. The distinction between AMF and cellular angiofibroma, both of which have a characteristic vascular network and spindle cell component, is relatively subtle. However, cellular angiofibroma is characterized by the presence of spindle cell lipomas and thick-walled vessels. Meanwhile, cellular angiofibromas lack ER and PR [
9].
Aggressive angiomyxoma(AAM) is most likely to be confused with AMF because it shares many features with AMF including age at presentation, location, clinical manifestations and pathological entities. However, AAM presents as a malignant, locally infiltrative, non-metastasizing stromal neoplasm with a strong tendency to recur. On microscopic examination, AMFs generally show much higher cellularity, more numerous blood vessels and more frequent plump or short spindle-shaped cells; in contrast, AAM cells are sparsely and diffusely distributed, without the characteristics of alternating density and aggregation around small blood vessels. AAMs show more distinctive myxoid degeneration than AMFs [
1,
17]. AMFs are characterized by the expression of vimentin, desmin and CD34, suggesting an undifferentiated mesenchymal tumor with preferential myofibroblastic differentiation. Desmin expression was previously thought to be specific for AMFs, but positive expression of desmin has been found in some cases of AAMs. Most AAMs are also positive for estrogen and progesterone receptors. Hence, desmin, estrogen receptor and progesterone receptor are no longer considered reliable markers for distinguishing AAMs from AMFs [
17]. After surgical treatment, 30% of AAMs have been found to relapse within 2 years [
1]. Since the morphology and IHC markers of AMF are similar to those of AAM, differentiation between these two tumors is largely based on the appearance of the tumor margins (AMFs are well demarcated).
As AMF is a commom perineum-site-specific stromal tumour, a benign neoplasm of dendritic fibromyxolipoma (DFML) in rare sites such as perineum regions should be differentiated from AMF. Zhang XJ et al. [
18] recently reported the case of a woman of similar age to our current case with a slow-growing, painless, subcutaneous tumor in the right inguinal and perineal regions which was diagnosed as DFML lately. Histologically, DFML is mainly composed of a proliferation of small spindle or stellate cells that are variably admixed with mature adipose tissue embedded within an abundant myxoid and collagenized stroma. Immunohistochemically, the spindle and stellate cells are strongly positive for vimentin, CD34, and bcl-2 antibodies but not for smooth muscle actin and desmin. The above-mentioned histopathological and immunohistochemical findings can easily distinguish AMF from DFML.
The pathological differential diagnosis should also include inflammatory myofibroblastic (IMT) which has myofibroblastic differentiation [
19]. These are rare benign lesions that are predominately located in the lung. Microscopic examination reveals a proliferation of regular myofibroblastic spindle cells arranged within a fibrous, myxoid or calcified stroma, associated with an inflammatory component of lymphocytes and plasmacytes but without blood vessels [
19]. Immunohistochemical studies show reactivity for vimentin, smooth muscle actin and ALK.
The treatment of choice for AMF is simple total excision, which is usually curative, and there are almost no incidences of recurrences or metastasis after complete excision, which confirms the benign nature of AMF [
20]. AMF shows no propensity for infiltrative growth.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PQ drafted the manuscript and performed the literature review. YL was responsible for collecting the patient material. ZW conducted the analysis of the histological documentation and corrected the manuscript.GBC performed image features. All authors read and approved the final manuscript.